Bastos-Oreiro, M, Iacoboni, G, Garcés, VN, Caballero, AC, Martínez, N, Delgado, J, Balaguer, A, Kwon, M, de Villambrosia, S, Hernani, R, Jimenez-Ubieto, A, Bailen, R, Zaberio, I, García-Sancho, A, Barba, P. Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study. Hemasphere. 2025; 9(2)DOI:10.1002/hem3.70077. PMID:39906687. IF:14.600(Q1/1D).

Cortellini, A, Brunetti, L, Di Fazio, GR, Garbo, E, Pinato, DJ, Naidoo, J, Katz, A, Loza, M, Neal, JW, Genova, C, Gettinger, S, Kim, SY, Jayakrishnan, R, El Zarif, T, Russano, M, Pecci, F, Di Federico, A, Awad, M, Alessi, J, Montrone, M, Owen, DH, Signorelli, D, Fidler, MJ, Li, MJ, Camerini, A, De Giglio, A, Young, L, Vincenzi, B, Metro, G, Passiglia, F, Yendamuri, S, Guida, A, Ghidini, M, Awosika, NO, Napolitano, A, Fulgenzi, CAM, Grisanti, S, Grossi, F, D'Incecco, A, Josephides, E, Van Hemelrijck, M, Russo, A, Gelibter, A, Spinelli, G, Verrico, M, Tomasik, B, Giusti, R, Newsom-Davis, T, Bria, E, Sebastian, M, Rost, M, Forster, M, Mukherjee, U, Landi, L, Mazzoni, F, Aujayeb, A, Dupont, M, Curioni-Fontecedro, A, Chiari, R, Pantano, F, Morabito, A, Leonetti, A, Friedlaender, A, Addeo, A, Zoratto, F, De Tursi, M, Cantini, L, Roca, E, Mountzios, G, Della Gravara, L, Kalvapudi, S, Inno, A, Bironzo, P, Barros, RD, O'Reilly, D, Bell, J, Karapanagiotou, E, Monnet, I, Baena, J, Macerelli, M, Majem, M, Agustoni, F, Cortinovis, DL, Tonini, G, Minuti, G, Bennati, C, Mezquita, L, Gorría, T, Servetto, A, Beninato, T, Lo Russo, G, Rogado, J, Moliner, L, Biello, F, Nana, FA, Dingemans, AM, Aerts, JGJ, Ferrara, R, Torri, V, Abu Hejleh, T, Takada, K, Naqash, AR, Garassino, M, Peters, S, Wakelee, H, Nassar, AH, Ricciuti, B. Determinants of 5-year survival in patients with advanced NSCLC with PD-L1=50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. Journal for ImmunoTherapy of Cancer. 2025; 13(2)DOI:10.1136/jitc-2024-010674. PMID:39904562. IF:10.600(Q1/1D).

Puig, L. Postswitching discontinuation of biosimilars in psoriasis: registry analyses fall short in addressing real-world biases. BRITISH JOURNAL OF DERMATOLOGY. 2025; 192(4)DOI:10.1093/bjd/ljaf003. PMID:39761694. IF:9.600(Q1/1D).

Neal, MA, Bolano-Diaz, CF, Richardson, M, Michell-Sodhi, J, Muni-Lofra, R, James, MK, Hollingsworth, KG, Hilsden, H, Wilson, I, Blamire, AM, Straub, V, Thelwall, PE, Diaz-Manera, J. Rapid Quantitative Assessment of Muscle Sodium Dynamics After Exercise Using 23Na-MRI in Dysferlinopathy and Healthy Controls. Journal of Cachexia Sarcopenia and Muscle. 2025; 16(1)DOI:10.1002/jcsm.13709. PMID:39900102. IF:9.100(Q1/1D).